What Is Expected in Phase 1 of a Research Procedure: An Evidence-Based Patient Guide

What is expected in phase 1 of a research procedure depends on the type of research, but it usually involves defining a clear question, reviewing existing knowledge, planning the method and putting safety and ethical safeguards in place. In a Phase 1 clinical trial, the focus is typically on early human safety, tolerability and how an investigational treatment behaves in the body.

Overview: what happens in Phase 1 research?

What is expected in phase 1 of a research procedure? The first phase generally establishes the purpose of the work, sets out a carefully controlled plan and begins collecting information in a safe, ethical way. When the term refers to a Phase 1 clinical trial, it is the earliest stage in which an investigational medicine, vaccine, device or treatment approach is studied in people.

Phase 1 clinical research is designed primarily to understand safety and tolerability. Researchers may also examine how the intervention is absorbed, distributed, changed and removed by the body, as well as early biological activity. It is not usually intended to prove that a new treatment works better than standard care.

Phase 1 can also be used more broadly in nursing, public health and healthcare improvement projects. In these settings, the first phase often means identifying a practical problem, developing a focused question and planning how reliable evidence will be gathered and assessed. The exact steps vary by research design, but ethical conduct, participant protection and transparent methods remain central.

How Phase 1 clinical research works

Before a Phase 1 study begins, researchers prepare a detailed protocol. This document explains the study purpose, who may participate, what assessments will occur, how the intervention will be given, what risks are anticipated and how safety will be monitored. An independent ethics committee or institutional review board reviews the study before participants are enrolled.

Early clinical studies commonly involve a relatively small number of participants. Depending on the intervention and condition, they may include healthy volunteers, people living with a specific disease or both. In oncology and some serious conditions, Phase 1 studies often enroll patients for whom standard options may be limited or unsuitable.

Many Phase 1 trials use a dose-escalation approach. Small groups receive different dose levels in a planned sequence, with safety data reviewed before higher doses are studied. Researchers may use blood tests, physical examinations, heart monitoring, symptom diaries, imaging or other assessments appropriate to the treatment being evaluated.

A research procedure is not the same as routine medical care. The investigational intervention may not provide direct benefit, and participants should continue to discuss their usual care needs with their treating clinician. The consent conversation should make clear what is known, what remains uncertain and what alternatives are available.

Who may be eligible to take part?

Each study has eligibility criteria, also called inclusion and exclusion criteria. These criteria help protect participants and ensure that the research can answer its question fairly. They may relate to age, diagnosis, disease stage, previous treatments, laboratory results, medicines being taken, pregnancy status or other health conditions.

Screening typically includes a discussion of medical history, a review of current medicines and supplements, and selected examinations or tests. Meeting the criteria does not automatically mean a person must participate. It means the research team can discuss whether the study may be appropriate and whether the person wishes to consider it.

Informed consent is an ongoing process rather than only a signature on a form. Participants should receive understandable information about the study purpose, visits, possible risks, expected inconveniences, privacy protections and possible alternatives. They can ask for time to decide, involve a trusted person and ask any question before agreeing.

• Participation should be voluntary and based on clear information.
• Eligibility requirements are designed for safety and scientific quality, not personal judgment.
• Participants should tell the team about all medicines, allergies and changes in health.
• People may decide not to participate without losing access to appropriate routine care.

What is step 1 of the research process?

Step 1 of the research process is usually identifying and clearly defining the problem or question to be studied. A useful research question is specific enough to guide the search for evidence and the choice of methods. For example, rather than asking whether rehabilitation helps, a team may ask whether a particular rehabilitation approach improves mobility for a defined group of patients over a stated period.

In healthcare, researchers often organize questions using frameworks such as PICO: patient or population, intervention, comparison and outcome. Not every question needs every element, but the framework can turn a broad concern into a question that can be researched carefully.

Once the question is defined, researchers review what is already known. This step helps avoid unnecessary duplication, identifies gaps in evidence and supports a method that is practical and ethically justified. A clear question also helps patients understand why a study is being done and what information it hopes to provide.

What are the 5 stages of evidence-based practice?

A widely used five-stage model of evidence-based practice is often described as: ask, acquire, appraise, apply and assess. These stages help healthcare professionals make decisions by combining the best available research evidence with clinical expertise and the individual patient’s values, needs and circumstances.

Ask means forming a focused clinical question. Acquire means searching for relevant, trustworthy evidence. Appraise means considering whether the evidence is reliable, meaningful and applicable to the situation. Apply means using the evidence alongside professional judgment and patient preferences. Assess means reviewing outcomes and considering whether the approach should be continued or improved.

Evidence-based practice does not mean that one research paper dictates care. Different study types answer different questions, and findings need to be interpreted in context. High-quality decision-making also recognizes that patients may have different priorities, practical circumstances and tolerance for possible risks or burdens.

What are the 7 steps of the EBP process?

Several seven-step models of the evidence-based practice, or EBP, process are used in healthcare education and clinical settings. Although terminology varies, a common version includes: cultivating a spirit of inquiry; asking a focused question; searching for the best evidence; critically appraising that evidence; integrating it with clinical expertise and patient preferences; evaluating the outcome; and sharing the results.

The first step, a spirit of inquiry, encourages clinicians and teams to question whether current practice is supported by up-to-date knowledge. The next steps move from a focused question to a structured search and careful appraisal. Appraisal considers study design, risk of bias, relevance, consistency and the balance between possible benefits and harms.

Integration and evaluation are especially important in real-world care. Even strong evidence may need to be adapted thoughtfully to an individual’s diagnosis, other medical conditions and goals. Sharing results supports learning across teams and can help improve care processes, while respecting patient privacy and research ethics.

Benefits, risks and recovery after a research procedure

Potential benefits of participating in a Phase 1 trial may include contributing to knowledge that could help future patients, receiving close study monitoring and, in some circumstances, gaining access to an investigational approach. However, direct personal benefit cannot be assumed. The research team should explain the realistic purpose of the study and any established treatment alternatives.

Risks depend on the intervention. A new medicine or device may cause side effects that are expected, unexpected, mild or serious. Study visits, blood sampling, imaging and other assessments can also involve discomfort, time commitments or practical burdens. Researchers reduce risk through eligibility criteria, gradual dose changes, safety monitoring and predefined rules for pausing or stopping a study.

Recovery is not always a single event. After a one-time procedure, a participant may be observed for a defined period and contacted later. For a medicine study, follow-up can continue for weeks or longer to monitor symptoms, laboratory results and delayed effects. Participants should follow the study instructions, attend required visits and report concerns without waiting for the next appointment.

Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals support international patients who need evaluation and treatment for a wide range of health conditions. Decisions about research participation should be made with qualified clinicians and the study team after a balanced discussion of the available options.

When to seek medical care

Participants should contact the research team as soon as possible if they develop new symptoms, worsening symptoms, a suspected side effect, an injury, a pregnancy or a change in medicines or supplements. The team needs this information to guide safe care and determine whether study procedures should be adjusted.

Urgent medical care is appropriate for severe or rapidly worsening symptoms, such as trouble breathing, chest pain, fainting, severe allergic-type symptoms, uncontrolled bleeding, new confusion or other signs of a medical emergency. In an emergency, people should seek local emergency help first and notify the research team when it is safe to do so.

People who are considering a study should also seek advice from their usual doctor or relevant specialist if they are unsure whether participation fits their medical needs. Asking questions is encouraged: participants can request clarification about risks, visit schedules, stopping rules, costs of usual care and what happens if they choose to withdraw.

Frequently asked questions

Is Phase 1 research safe?

Phase 1 research is designed with safety as the main priority, but no research participation is completely without risk. Protocol review, informed consent, careful eligibility criteria and close monitoring are used to reduce risk. The study team should explain known and possible unknown risks before enrollment.

How long does a Phase 1 clinical trial last?

The length varies widely according to the intervention and study design. Some studies involve a single visit and short observation period, while others include repeated treatment visits and follow-up over months. The consent materials should outline the expected schedule.

Do Phase 1 trial participants receive a treatment that works?

A Phase 1 trial may provide an investigational intervention, but its effectiveness is often not yet established. The main purpose is usually to learn about safety, tolerability and an appropriate dose or method of use. Participants should not assume they will receive direct medical benefit.

Can someone leave a research study after joining?

In most situations, participation is voluntary and a person can choose to withdraw. It is helpful to discuss this decision with the study team, because they can explain any safety follow-up that may be recommended. Withdrawing from a study should not prevent a person from receiving appropriate medical care.

What is the difference between clinical research and evidence-based practice?

Clinical research generates new knowledge by studying questions in a planned, ethical way. Evidence-based practice uses the best available research evidence together with clinical expertise and patient preferences to guide care. Research findings may later become part of evidence-based practice after careful evaluation.

Why are blood tests and follow-up visits common in Phase 1 studies?

They help researchers monitor safety and understand how an investigational intervention affects the body. Tests may identify changes before a participant notices symptoms and can help guide decisions about continued participation. The specific assessments depend on the study protocol.

References

• World Health Organization
• U.S. Food and Drug Administration
• National Institutes of Health
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
• Centre for Evidence-Based Medicine

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.